Trial Profile

Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 25 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Idebenone (Primary)
Indications Leber's hereditary optic atrophy
Focus Expanded access; Therapeutic Use
Acronyms US EAP LHON
Sponsors Santhera Pharmaceuticals

Most Recent Events

14 Apr 2015 According to a Santhera Pharmaceuticals media release, in May 2014, Santhera re-filed a Marketing Authorization Application for idebenone [Raxone] to treat Leber's Hereditary Optic Neuropathy (LHON) with efficacy data from the pivotal RHODOS study (see profile 700227741) and additional clinical efficacy data from this expanded access program.
05 Feb 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com